Indukern mantiene las ventas en 456 millones e invierte un 2% más

2025 was a year of consolidation and growth for Grupo Indukern, as indicated by its vice-president executive Raúl Díaz-Varela in the sustainability report. The pharmaceutical holding, owned by the Díaz-Varela family, maintained its revenue at 456 million euros, a 0.4% increase from 454 million in 2024, according to the company's sustainability report.

The company, which consists of Kern Pharma, focused on human health, and Calier, specializing in veterinary medicine, saw both businesses achieve their 2024 revenue, albeit with moderate growth.

Kern Pharma, which generated 362 million euros in 2025, an increase of 2.3% year-over-year, earned 50% of the group's revenue, thanks to generic medicines. Biosimilars contributed 24% of the income, while personal care products made up 16%. The group highlighted the launch of the anti-inflammatory gel Diclokern Forte in a 150-gram format and the expansion of its international and third-party manufacturing operations.

Kern Pharma distributes its products in more than 80 countries, contributing nearly 20% of its annual sales.

On the other hand, Calier's revenue growth slowed in 2025, after a 28% surge in 2024, with a reported 93 million euros, a 2.2% increase. The veterinary subsidiary implemented a customer-centric strategy and introduced various processes to respond swiftly, reliably, and efficiently to market demands. Indukern invested 17.7 million euros in 2025, a 2.3% increase from the previous year.

Out of the total, 10.5 million euros were allocated to bolster Kern Pharma's operations. The Catalan group operates three plants in Argentina, Colombia, and Uruguay, and four plants in Spain, located in Terrassa (the company's headquarters), Les Franqueses del Vallés, León, and Murcia.